Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 17, 2009

Synta Obtains $10M from GSK under Cancer Deal

  • Synta Pharmaceuticals achieved an operational milestone triggering a $10 million payment from GlaxoSmithKline (GSK) under its collaboration for elesclomol. The drug is currently being studied in combination with paclitaxel in a Phase III trial in metastatic melanoma.

    In October 2007, Synta and GSK inked a deal covering elesclomol that was worth $965 million. Synta has earned a total of $130 million to date, including $80 million up front and $25 million for milestones achieved in October and  $15 million for milestones achieved in December 2008.

    The company is eligible for a total of $585 million in precommercial milestone payments: $150 related to development in melanoma and the remainder related to other cancer indications.  Synta is also eligible to $300 million in sales milestones, 40-50% share of operating profits in the U.S., and double-digit royalties on ex-U.S. sales.

    Elesclomol is an investigational first-in-class oxidative stress inducer that triggers apoptosis in cancer cells. Enrollment for the Phase III study was completed earlier this month.

     

    ---

    To comment on this story, go to BLOGbiotech.



Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »